Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2016-01-19 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos advances CF clinical development
Regulatory Filings Classification · 95% confidence The document is a press release issued by Galapagos NV regarding the progress of their cystic fibrosis clinical development programs and a milestone payment from their partner, AbbVie. It provides updates on clinical trial phases, drug candidates, and collaboration details. It does not constitute a formal financial report (10-K, IR), a transcript, or a governance document. As it is a general corporate announcement regarding business operations and regulatory milestones, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for general corporate news releases. Q1 2016
2016-01-19 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. The document includes exhibits such as a License and Collaboration Agreement and a press release. The document length is short (1598 characters), and it primarily serves as a regulatory filing to disclose material information to the SEC. It does not contain comprehensive financial statements or detailed financial analysis, nor is it an announcement of voting results, management changes, or other specific categories. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-01-19 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F, often including press releases or other announcements. The document references an attached press release (Exhibit 99.1) dated January 13, 2016. The document length is short (1498 characters), and it primarily serves as a regulatory filing to report the press release rather than containing substantive financial data or detailed reports. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and does not qualify as an Annual Report, Interim Report, or other specific report types.
2016-01-19 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. The document references a press release attached as Exhibit 99.1 but does not contain detailed financial statements or substantive financial data itself. The document length is short (1498 characters), and it primarily serves as a regulatory filing to report the press release. According to the rules, such filings that do not contain full reports but serve as announcements or regulatory disclosures should be classified as Regulatory Filings (RNS).
2016-01-19 English
Galapagos rapporteert vooruitgang in klinische ontwikkeling taaislijmziekte
Earnings Release Classification · 99% confidence The document is dated January 19, 2016, and is titled as an update on clinical development progress for cystic fibrosis, mentioning specific drug candidates (GLPG2222, GLPG2665, etc.), milestone payments, and upcoming study phases (Phase 1, Phase 2). It details scientific progress and partnership updates with AbbVie. This content structure—a detailed update on pipeline progress, clinical trials, and financial milestones related to drug development—is characteristic of an Earnings Release (ER) or a comprehensive update often accompanying financial reporting periods, but since it focuses heavily on operational and clinical milestones rather than just the final quarterly numbers, it aligns best with an Earnings Release (ER) which typically includes key operational highlights alongside financial results, or potentially an Investor Presentation (IP) if it were structured as slides. Given the format is a press release announcing key operational and financial progress (milestone payment received, start of Phase 1 study), 'Earnings Release' (ER) is the most appropriate classification for this type of operational/financial update announcement, even though it is not explicitly labeled 'Q4 Earnings'. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR) as it is a specific press release update. It is not an RPA because it contains substantial content, not just an announcement of another document. Q1 2016
2016-01-19 Dutch
Galapagos and Gilead cleared by US FTC to close their global partnership on filgotinib
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the regulatory approval (FTC) of a global collaboration and licensing agreement between Galapagos and Gilead Sciences. It details the financial terms of the deal, including an upfront payment and an equity investment. Because this document describes a specific corporate transaction involving financing and strategic partnership, it falls under the 'Capital/Financing Update' category.
2016-01-13 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.